Search results for " biologic"
								 					Article
				
				Maximum Output Starts with Optimized Upstream Processing
								Significant growth in the development and manufacturing of biologics—from traditional recombinant proteins and monoclonal antibodies (mAbs) to advanced multispecifics, antibody-drug conjugates, viral …								
								 					Article
				
				Ensuring Viral Safety of Viral Vaccines and Vectors
								However, because biological materials—cell substrates and often animal-derived products—are used in their manufacture, viral vaccines and vectors are at risk of contamination from micro-organisms, suc…								
								 					Article
				
				An Integrated Approach to Ensure the Viral Safety of Biotherapeutics
								By Mark Plavsic 
	Use of continuous cell lines in the manufacture of biological therapeutic products, such as vaccines, recombinant proteins, and monoclonal antibodies, is associated with the concom…								
								 					Article
				
				Prescribing Caution for Biosimilars
								These legislative efforts represent a significant step in recognizing the important and complex role biologic medicines play in the future of healthcare and chronic disease management. They are also a…								
								 					Article
				
				Regulatory Challenges in the QbD Paradigm
								This model is especially evident in FDA's Center for Drug Evaluation and Research (CDER) as used for therapeutic biological products, such as proteins and monoclonal antibodies. These products were tr…								
								 					Article
				
				Pharma Investments Reflect Key Industry Trends
								First is the shift to biologic-based drugs, which has occurred along with a dramatic increase in the productivity, mainly in terms of much higher titers, of biopharmaceutical processes. “While demand …								
								 					Article
				
				Elucidating Biosimilars Characterization
								The growth corresponds to a 20% increase from last year’s figures and accounts for approximately 2% of the overall biologics market. Although narrowly focused on only a small number of therapy areas a…								
								 					Article
				
				Reimagining Affordable Biosimilars
								With an anticipated valuation of over $200 billion by 2022, this popularity of protein-based biologics can be attributed to their unique target specificity in protein–protein interactions for the trea…								
								 					Article
				
				Microbiological Testing: Time is of the Essence
								Conventional protocols no longer suitable for traditional biologics
	
	Microbiology testing of pharmaceutical products is performed with a view to detection, enumeration, and identification of microbi…								
								 					Article
				
				Preclinical Evaluation of Product Related Impurities and Variants
								Not all biologics can be subjected to a uniform panel of tests owing to their differences in their modes of action as well as their inherent biological/chemical complexities (8). In this 38th article …